The effects of the bifunctional agonist BU08028 on cocaine self-administration and reinstatement in rhesus monkeys
Year: 2026
Type: dissertation
Abstract: Cocaine use disorder (CUD) remains a significant public health concern, yet no FDA-approved pharmacotherapies are currently available. Bifunctional agonists that stimulate both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors have shown promise in preclinical studies and may represent a novel treatment strategy. This thesis evaluated the bifunctional MOP/NOP agonist (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6 methoxy morphinan- 7-yl]-3,3-dimethylpentan-2-ol (BU08028) in nonhuman primate models of cocaine reinforcement and relapse-related behavior. In Chapter 1, the effects of acute and chronic BU08028 administration on cocaine self-administration were assessed in rhesus monkeys responding under a fixed-ratio schedule of reinforcement. Acute BU08028 enhanced cocaine reinforcement in two of eight monkeys, whereas chronic administration decreased the reinforcing effects of a lower cocaine dose for several weeks without developing tolerance, and with minimal effects on food-maintained responding. In Chapter 2, the ability of BU08028 to reinstate extinguished cocaine-maintained responding was evaluated using an extinction–reinstatement procedure. Cocaine reliably reinstated responding, and buprenorphine produced reinstatement in some monkeys, whereas BU08028 failed to reinstate responding in all monkeys. Together, these findings indicate that chronic BU08028 reduces cocaine reinforcement while lacking relapse-promoting effects, supporting continued evaluation of bifunctional MOP/NOP agonists as potential pharmacotherapies for cocaine use disorder.
Author: Costa, Marissa Brianne
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Funder: National Institutes of Health
OpenAlex ID: W7169637518
